Trial Information
Inclusion Criteria:
- Thirty type 2 diabetes mellitus with stable coronary disease
- Aged 18-80 year-old
Exclusion Criteria:
- Previous underwent coronary artery bypass surgery or percutaneous angioplasty
- Under insulin injection patients
- Renal or hepatic function impairment
- Pregnant women
- Poor BP control(BP>175/105 mmHg)
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
Number of endothelial progenitor cells, endothelial function(FMD)
Outcome Time Frame:
3 months
Safety Issue:
No
Principal Investigator
Jaw-Wen Chen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Division of Cardiology, Taipei Veterans General Hospital
Authority:
Taiwan: Institutional Review Board
Study ID:
VGHIRB 98-10-02
NCT ID:
NCT01038050
Start Date:
October 2009
Completion Date:
December 2010
Related Keywords:
- Type 2 Diabetes Mellitus
- Coronary Artery Disease
- Endothelial progenitor cell
- endothelial function(FMD)
- Gingko Biloba Extract
- Type 2 Diabetes mellitus
- Stable coronary artery disease
- Endothelial progenitor cells Numbers
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2